# Geron (GERN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GERN
## Company Profile
- Ticker: GERN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Hematology
## Stock Data
- Close: 1.57 USD
- Market cap: 750579539.5799999 USD
- Last updated: 2026-08-12
## Business Overview
### Telomerase-Targeted Hematology Company
Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells.
### RYTELO in Lower-Risk MDS
RYTELO, or imetelstat, is a first-in-class oligonucleotide telomerase inhibitor approved in the United States and European Union for defined adults with transfusion-dependent anemia caused by lower-risk myelodysplastic syndromes. The therapy is administered by intravenous infusion every four weeks.
### Differentiated Clinical Profile
RYTELO is intended for patients who have not responded to, have lost response to or are ineligible for erythropoiesis-stimulating therapy. Evidence from the Phase 3 IMerge study supports its ability to produce periods of red-blood-cell transfusion independence, making reduction of transfusion burden central to its clinical value proposition.
### Commercialization Footprint
Geron directly commercializes RYTELO in the United States and is assessing how best to commercialize the product in Europe while preserving the economics and pricing integrity of the broader franchise.
## Why The Stock Is Moving

As of Aug 12, 2026, GERN closed down 3.68% at $1.57. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-05 11:00 EST — [Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/GERN/geron-corporation-reports-second-quarter-2026-financial-results-and-recent-busin-c583ce9f) — Source: Geron
- 2026-07-22 20:01 EST — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31c72267) — Source: Geron
- 2026-07-22 11:00 EST — [Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/GERN/geron-plans-to-announce-second-quarter-2026-financial-results-on-august-5-2026-cc0edc91) — Source: Geron
- 2026-07-14 20:26 EST — [Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dee5e3ab) — Source: Geron
- 2026-07-13 12:00 EST — [Geron Announces Appointment of Chinmaya Rath as Chief Business Officer](https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-officer-bb96f9cb) — Source: Geron